Meeting Banner
Abstract #0280

DSC-MRI Measures of Relative Cerebral Blood Volume (rCBV) as a Prognostic Marker for Progression-Free and Overall Survival in Recurrent Glioblastoma: Results from the ACRIN 6677/RTOG 0625 Multi-Center Trial

Kathleen M. Schmainda 1 , Zheng Zhang 2 , Jerrold Boxerman 3 , Melissa Prah 1 , Bradley Snyder 2 , Devyani Bedekar 4 , A Gregory Sorensen 5 , Mark R Gilbert 6 , and Daniel P Barboriak 7

1 Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 2 Center for Statistical Sciences, Brown University, Rhode Island, United States, 3 Diagnostic Imaging, Rhode Island Hospital, Rhode Island, United States, 4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 5 Massachusetts General Hospital, Massachusetts, United States, 6 Neuro-Oncology, University of Texas, Houston, Texas, United States, 7 Radiology, Duke University, Durham, North Carolina, United States

RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). In this study of 23 patients the percent changes in both normalized and standardized rCBV, derived from DSC-MRI, are predictive of progression free survival (PFS) and overall survival (OS) when measured at 2 and 16 weeks following treatment initiation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here